As a standalone GLP-1, liraglutide differs from semaglutide in several ways
caution and clinical monitoring are appropriate People taking insulin or insulin secretagogues (such as sulphonylureas), where the risk of hypoglycaemia may be increased, and dose adjustment of the concomitant agent may be needed Those with active or unstable diabetic retinopathy , given the potential for transient worsening with rapid glycaemic improvement People taking oral medicines with a narrow therapeutic index , where delayed gastric emptying could affect drug absorption Regarding medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN2): animal studies with GLP-1 receptor agonists have shown thyroid C-cell changes, and some regulatory authorities have issued precautionary warnings
However, there are alternative medications to treat diabetes, such as insulin, Metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitors, meglitinides, thiazolidinediones and alpha-glucosidase inhibitors
Accordingly, immunohistochemistry revealed that recombinant CXCL10 treatment sharply increased the level of p-FOXO3A in the nucleus of PMFs from the CXCL10 group, whereas IL18R1 antibody treatment reversed this increase to levels close to those of the control in the 10+18ab group (Fig
